Spyre Therapeutics
SYRE
33 hedge funds and large institutions have $30.4M invested in Spyre Therapeutics in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
43% more funds holding
Funds holding: 23 → 33 (+10)
0.39% more ownership
Funds ownership: 1.54% → 1.92% (+0.39%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $38.5M → $30.4M (-$8.06M)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.81M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$5.24M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$940K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$553K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$320K |
| 2 |
SCM
Sio Capital Management
New York
|
-$223K |
| 3 |
Squarepoint
New York
|
-$91K |
| 4 |
Renaissance Technologies
New York
|
-$60.8K |
| 5 |
Bank of New York Mellon
New York
|
-$43.1K |
SYRE Hedge Fund Activity: Q2 2017 in Review
33 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2017, worth a combined $30.4M — down 21% from $38.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SYRE positions and 2 closed out — a net gain of 10 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $8.81M. The largest seller was Jennison Associates, cutting an estimated $320K.
- 33 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2017, up from 23 in Q1 2017.
- Funds reported $30.4M of Spyre Therapeutics stock for Q2 2017, down 21% quarter-over-quarter.
- 12 funds opened new Spyre Therapeutics positions in Q2 2017 and 2 closed out, a net change of +10 holders.
- The largest Spyre Therapeutics buyer in Q2 2017 was Nantahala Capital Management, an estimated $8.81M added.
- The largest Spyre Therapeutics seller in Q2 2017 was Jennison Associates, an estimated $320K sold.
Based on aggregated 13F filings for Q2 2017.